News
PRE
15.38
+0.59%
0.09
Prenetics Executives Boost Personal Share Purchases to $2.75 Million After Earnings
TipRanks · 1d ago
Prenetics announces executive open market share purchases
TipRanks · 1d ago
Weekly Report: what happened at PRE last week (0223-0227)?
Weekly Report · 3d ago
Prenetics announces launch of Daily Ultimate Essentials PRO
TipRanks · 02/23 14:15
Prenetics Global Introduces Daily Ultimate Essentials PRO
Benzinga · 02/23 14:02
Prenetics Launches IM8 Daily Ultimate Essentials PRO and Adds Two New Flavours
Reuters · 02/23 14:00
Weekly Report: what happened at PRE last week (0216-0220)?
Weekly Report · 02/23 10:18
Prenetics Launches IM8 Daily Ultimate Essentials PRO — A Clinical Formula with Two New Flavours
Barchart · 02/23 08:00
Analysts Offer Insights on Healthcare Companies: Reviva Pharmaceuticals Holdings (RVPH) and Prenetics Group (PRE)
TipRanks · 02/20 06:40
Top Small-Cap Stocks Leading The Market Rotation
Seeking Alpha · 02/18 18:24
Nasdaq Surges Over 1%; US Durable Goods Orders Fall In December
Benzinga · 02/18 17:59
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 02/18 17:05
Prenetics Posts Record 2025 Results as IM8 Hits $120 Million ARR and Drives Strategic Refocus
TipRanks · 02/18 14:47
Prenetics Global GAAP EPS of -$3.79 misses by $1.25, revenue of $92.39M beats by $2.25M
Seeking Alpha · 02/18 14:36
Prenetics completes $70M Insighta sale to Tencent
TipRanks · 02/18 14:30
Prenetics Completes $70 Million Insighta Stake Sale to Tencent
Reuters · 02/18 14:25
Prenetics Global Q4 revenue surges 457% 
Reuters · 02/18 14:21
Prenetics reports Q4 EPS ($1.77) vs. ($1.01) last year
TipRanks · 02/18 14:20
Prenetics sees FY26 IM8 revenue $180M-$200M
TipRanks · 02/18 14:20
BRIEF-Prenetics Global Q4 Revenue USD 36.6 Million
Reuters · 02/18 14:12
More
Webull provides a variety of real-time PRE stock news. You can receive the latest news about Prenetics Ltd through multiple platforms. This information may help you make smarter investment decisions.
About PRE
Prenetics Global Ltd is a company principally engaged in the provision of diagnostic and preventive products and services. The Company operates its business through two segments. The Diagnostics segment is mainly engaged in the sale of precision oncology testing services. The Prevention segment is mainly engaged in the design and sale of genetics testing, including update services, and stool-based deoxyribonucleic acid (DNA) tests for early colorectal cancer screening. The Company's products and services include CircleDNA, ACTOnco, ACTHRD and other products. The in-house developed consumer genetic testing product, CircleDNA, offers comprehensive DNA tests capitalizing on in-house developed testing algorithm. ACTOnco is a comprehensive cancer test used to guide treatment selection for major solid tumors. ACTHRD is a test for the homologous recombination deficiency status of cancer patients. The Company is also engaged in consumer health products by a new health and wellness brand IM8.